Effect of recombinant human erythropoietin in a rat model of moderate chronic renal failure – focus on inflammation, oxidative Stress and function/renoprotection

Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy....

ver descrição completa

Detalhes bibliográficos
Autor principal: Garrido, P. (author)
Outros Autores: Reis, F. (author), Costa, E. (author), Almeida, A. (author), Parada, B. (author), Teixeira-Lemos, E. (author), Santos, P. (author), Alves, R. (author), Sereno, J. (author), Pinto, R. (author), Tavares, C.A. (author), Figueiredo, A. (author), Rocha-Pereira, P. (author), Belo, L. (author), Santos-Silva, A. (author), Teixeira, F. (author)
Formato: article
Idioma:eng
Publicado em: 2010
Assuntos:
Moderate chronic renal failure
Erythropoietin treatment
Renoprotection
Proliferation
Inflammation
Oxidative stress
Texto completo:http://hdl.handle.net/10400.14/3018
País:Portugal
Oai:oai:repositorio.ucp.pt:10400.14/3018

Texto Completo

http://hdl.handle.net/10400.14/3018

Registros relacionados